By Bahram Hassanpourfard, Epidemiologist
Weekly briefing · 14 to 20 November 2026
Public health and prevention
Global health authorities said the United States has lost its measles elimination status after several states faced their worst outbreaks in nearly three decades, and the CDC and partners set out plans to stop the outbreaks and restore it. It is a stark sign of how far immunisation has slipped in a high-income country. In the UK, the seventh report of the Covid-19 Inquiry found that failures in testing, contact tracing and support for people isolating left the country struggling to contain the virus early on, and warned that preparation for the next pandemic must start now. The UK National Screening Committee also opened a consultation on the evidence for ovarian cancer screening.
Antimicrobial resistance was the focus of European Antibiotic Awareness Day on 18 November. ECDC’s fourth rapid risk assessment on carbapenem-resistant Enterobacterales found the situation in the EU/EEA worsening and treatment options being lost. PAHO warned of rising resistance to antibiotics used against serious infections in the Americas. New IDSA guidance on resistant Gram-negative infections puts resistance mechanisms and rapid diagnostics at the centre of treatment choice.
Healthcare providers
Emergency care in Wales drew the sharpest warning of the week: the Royal College of Emergency Medicine said new statistics revealed the true scale of the crisis in emergency departments and demanded immediate government action before winter. The Welsh Government made a statement on emergency and acute care and set out surgical hubs to protect routine operations from cancellation. England’s hub model is further advanced, with three more hubs winning GIRFT accreditation, taking the total to 94 of the 128 in operation. Norfolk and Norwich University Hospitals received £1.97m from the NIHR to expand commercial research, relevant to sponsors placing trials in the NHS. In general practice, practices sought clarity on NHS England’s reimbursement scheme for additional GP sessions, including those worked by self-employed and agency locums. The RCGP responded to Alan Milburn’s review of youth unemployment, which recommends reforming the fit note system for young people.
Research and trials
A malaria study delivered the week’s clearest clinical caution: a monoclonal antibody that holds promise for prevention interfered with a new vaccine when the two were used in babies, raising doubts about combining them. A secondary analysis of the SAVE-MORE trial in The Lancet linked progression to severe respiratory failure in Covid-19 with an inflammatory amplification programme. It also found anakinra associated with smaller changes in the proteins involved, giving biological context to the trial’s clinical benefit. Novartis reported a mid-stage win for its eczema drug and said it is working towards restarting trials of its autoimmune CAR-T therapy.
Deals and markets
AI-driven drug discovery attracted record capital as Isomorphic Labs raised a $5bn Series C, the largest private raise in biotech history and its second multibillion-dollar round in six months, and added Merck as an oncology small-molecule partner. The UK benefited from the same trend when Flagship Pioneering chose London for its first company-creation unit outside its home city, committing £100m to build AI-native platform companies.
Johnson & Johnson agreed to buy Ollin Biosciences for $2.2bn upfront and up to $3.3bn in total, gaining a phase 3 bispecific antibody that would challenge Roche’s Vabysmo in a crowded eye disease market. Pfizer entered in vivo CAR-T by paying $330m upfront to China’s Starna Therapeutics for rights outside Greater China to three pre-IND autoimmune programmes, in a deal worth up to $2.6bn. Its timing was notable, as a bipartisan congressional commission used its final weeks to warn about licensing deals with Chinese biotechs. Bloomberg reported that Sanofi, facing the loss of exclusivity on Dupixent, is considering acquiring Insmed, developer of the respiratory medicine Brinsupri.
Approvals and safety
The White House withdrew Heidi Overton’s nomination as FDA commissioner amid uncertain Senate support, though analysts said the move should not disrupt the agency. Approvals continued regardless. Sanofi’s venglustat (Infilbray) became the first treatment for the neurological symptoms of type 3 Gaucher disease. Regeneron’s Alnylam-licensed siRNA cemdisiran (Livsayis) was cleared for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, the second new drug for the disease approved within a week. GSK won US accelerated approval for neladalkib (Nelkarmi), the second lung cancer drug from its $10.6bn Nuvalent acquisition. Roche’s Gazyva had been approved for primary membranous nephropathy on 13 November, the day before the week began.
On safety, a medicines alert warned that patients with hypoparathyroidism prescribed alfacalcidol had suffered significant calcium fluctuations, including severe hypocalcaemia requiring emergency treatment. Health Canada flagged Taro-candesartan lots that may contain esomeprazole capsules. The FDA issued an early alert on B. Braun’s Caresite luer access device, whose valve may not fully close after disconnection.



